Biography
Biography: Kamala K Maddali
Abstract
Immunotherapy enables the immune system to recognize tumors; insights into immunotherapy biomarker testing, especially PD-L1 IHC and; choosing the best patients for immunotherapy with the use of integrated biomarker panels. Combination regimens of immuno-oncology agents and targeted drugs may represent the next generation of cancer treatments and could result in improved outcomes and prolonged patient survival. This talk will focus on immunooncology advancements and a review of latest drug targets. In addition to the underlying science, we will focus on the practical aspects of targeting the PD1:PD-L1 interaction. We will discuss our perspectives of supporting PD-L1 as a pharmacodynamic end point and companion diagnostic. Additionally, we will focus on case studies, where we monitored PD-L1 expression and the variable sensitivity, specificity and dynamic range of three anti-PD-L1 antibodies in a cohort of 52 primary DLBCL patients. CGI believes that this work is essential in developing durable and reliable immune biomarkers and companion diagnostics for selecting lymphoma patients most likely to benefit from immune-checkpoint therapy.